A rare intracranial brain-recording study revealed that tirzepatide, a GLP-1 and GIP receptor agonist, temporarily silences craving-related neural activity in a key reward circuit of the brain. Using implanted electrodes in a patient with treatment-resistant obesity and loss of control eating, researchers observed that the drug initially shut down signaling in the nucleus accumbens.
A rare intracranial brain-recording study revealed that tirzepatide, a GLP-1 and GIP receptor agonist, temporarily silences craving-related neural activity in a key reward circuit of the brain. Using implanted electrodes in a patient with treatment-resistant obesity and loss of control eating, researchers observed that the drug initially shut down signaling in the nucleus accumbens.
Share this Article
Recommended